Medical Need






LTX-315 is an oncolytic immunotherapy. Time lapse study with confocal microscopy shows that the human melanoma cell (A547) is killed within minutes by LTX-315. (Courtesy of L.M. Eike and B. Sveinbjørnsson, UiT)
Presentation of LTX-315 – the discovery and it’s mode of action.

LTX-315, a powerful Oncolytic Peptide Immunotherapy (OPI)
Lytix Biopharma's drug candidate LTX-315 induces a potent stimulation of an extended range of tumour specific T-cells attacking cancer - increasing patient specific immune response.

LTX-315 is an ideal combinations partner for immune checkpoint inhibitors (ICIs), it has the potential to augment efficacy without adding toxicity.

The drug candidate has a potential for multiple, high value indications.

LTX-315, clinical activity

  • Partial and complete responses in injected tumours
  • Increases tumour infiltrating lymphocytes (TILs) in treated tumours indicating a systemic immune respons
  • Has a favourable side effect profile

LTX-315, preclinical activity

  • Complete regression of all solid tumours investigated
  • Abscopal effect in several tumour models
  • Induces tumour spesific and T-cell mediated protective immune repons 
  • Strong synergy in different cancer models in combination with immune checkpoint inhibitors
  • Equally active against drug-resistant and drug-sensitive cancers

LTX-315, mode of action

  • Induces the release of potent immune stimulants from mitochondria that activates immune cells
  • Induces the release of an extended range of tumour specific antigents from the cancer cells
  • Triggers a strong and diverse tumour specific T-cell respons

    Mode of action

LTX-315, clinical trials

  1. A Phase I dose-Escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour (Study C08-315-01); Completed Details available at

  2. A Phase I combination, immunologic study of LTX-315 with GV1001 in patients following surgery with curative intent for malignant tumours (Study C09-315-02); Completed Details available at

  3. A Phase I dose-Escalation Study of LTX-315 in Patients With Transdermally Accessible Tumours (Study C12-315-03); Recruiting Details available at

Information about the ongoing study (Only in Norwegian)